Niche tech leverage iCeutica specializes in SoluMatrix Fine Particle Technology to repurpose and enhance existing drug compounds, creating potential for partnerships to co-develop or out-license improved formulations that meet regulatory and market needs.

FDA approved base There are four FDA-approved therapies using iCeutica technology (Zorvolex, Tivorbex, Vivlodex, Yonsa), signaling a credible track record that can be leveraged to approach oncology, pain management, and niche indications with faster regulatory pathways or expanded label opportunities.

Strategic partnerships Current model includes collaborations with selected pharma partners, presenting opportunities to propose joint development, licensing, or commercialization deals to extend the SoluMatrix platform to additional molecules.

Market readiness With a revenue range of 1–10 million and a focused product portfolio, target mid-market pharma and specialty companies seeking revitalized formulations or differentiated pain and cancer therapies to expand their pipelines.

Growth signals Private status, small team size, and a proven track record of clinically meaningful products provide an agile partner profile for quick decision-making and rapid due diligence in BD conversations, especially against larger competitors.